about
A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling.Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cellsC5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling.Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.Downsizing a human inflammatory protein to a small molecule with equal potency and functionality.Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists.PAR2 Modulators Derived from GB88.Pathway-selective antagonism of proteinase activated receptor 2.Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.Structure, function and pathophysiology of protease activated receptors.Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3aPotent Small Agonists of Protease Activated Receptor 2.Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a.A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells.Mapping transmembrane residues of proteinase activated receptor 2 (PAR2) that influence ligand-modulated calcium signaling.Biased Signaling by Agonists of Protease Activated Receptor 2.Potent complement C3a receptor agonists derived from oxazole amino acids: Structure-activity relationships.Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2.Differential immunological profiles herald magnetic resonance imaging-defined perioperative cerebral infarction.Transfusion of packed red blood cells at the end of shelf life is associated with increased risk of mortality - a pooled patient data analysis of 16 observational trialsAn antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in ratsAntagonism of Protease-Activated Receptor 2 Protects against Experimental ColitisInflammation and lung injury in an ovine model of fluid resuscitated endotoxemic shockExtracorporeal membrane oxygenation (ECMO) and the acute respiratory distress syndrome (ARDS): a systematic review of pre-clinical modelsEndothelialized flow models for blood transfusion researchRecruitment manoeuvres dislodge mucus towards the distal airways in an experimental model of severe pneumoniaPre-clinical study protocol: Blood transfusion in endotoxaemic shockAdministration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performanceNeuron-Specific Enolase and Matrix Metalloproteinase 9 Signal Perioperative Silent Brain Infarction During or After Transcatheter Aortic Valve ImplantationProtease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidneyPharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritisHurdles to Cardioprotection in the Critically IllLow flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuitEffect of ex vivo extracorporeal membrane oxygenation flow dynamics on immune responseMesenchymal stem cells may ameliorate inflammation in an ex vivo model of extracorporeal membrane oxygenation
P50
Q30420969-DFF404F0-3645-419B-A4D8-D12A5DB3C709Q33745121-4B851631-31F9-4DD4-B720-B5E5B1C2C298Q34309482-44288D6D-45DA-46C3-8969-1946E1BF4539Q34365510-5C223436-5C20-42BA-92EA-F1B2A25F098EQ34386483-193AC28B-F176-4C39-8F84-8E98C32D3447Q34522748-2F521946-34DE-42D9-95DD-31029ABF6FC2Q34547663-C322B78F-33A7-4C85-9851-04ED2EAD9124Q34571419-73C7E273-48A8-4AD0-9384-C98BC1C71A24Q36024903-5600EFA2-7BAD-4524-B83C-BDB285C240C2Q37635262-FDABFC25-AC62-4A3B-A65F-CE635F3277D6Q37833353-58A2FFB4-FB50-4D8C-BD41-6AA18378DDB0Q38806987-A33DE48D-41DF-4E4D-B942-EE7F0FD52B1AQ41516139-0C92D95B-A156-4098-BE99-77E229437214Q43083912-1BB784DB-850E-4D10-AD5A-23C54BFF842DQ44641990-89875E80-0C09-4443-8110-92DC5E12B8D6Q47269232-B16C700B-081C-499D-85B0-787EDB7AA5F4Q47846277-5AE163BD-B5EB-4D0E-BB81-9AC2AC8484C4Q47980109-D7508877-7CE8-42AB-86C2-FE6E1D4840BEQ52905401-697400DB-4648-495D-8AB5-19749B0E5D32Q52911677-B7C89AAA-E8B6-4B1C-9125-969F0C1205E4Q55455975-70C70536-8C05-494F-B6E4-87184F14B8FDQ56888369-C000FCD4-DFAE-4BA4-8542-CFBA8D0940BDQ57080827-1BEC9F40-CB21-4452-975A-0A6A9D73D79AQ57080828-1695DAEB-6FE5-4713-8855-7DEADC9A9B6FQ59329666-0CF5874B-EF77-42B6-8E69-20EE6CB6E0D8Q64055431-C1EF5092-2134-44B0-A6DC-829417A2646AQ64077449-049E33CD-44C5-4A22-ACED-57794258DA6FQ64133180-553DC4EE-992C-4913-935D-8905EE645720Q64274258-295136A5-C450-4DF8-B4BD-7AF08DF7525CQ88286826-FDF8C588-E220-47B1-9565-4CFA39EC72AAQ90025350-9BB11F9E-BDF2-4D58-8251-672A12816849Q91954756-170C5A6A-E016-426F-87B5-1D1E445F4CEBQ91965618-66790167-74D0-47E7-8E64-5DC409FD9081Q92454801-E992F0B8-6791-488C-A9B5-5E73C724BAB5Q92738999-4BB769C2-6274-4AB5-A861-C0287208932DQ92982491-085C11F6-2DEB-4E83-AC77-F6EE7419AF78Q92982517-7B493BA6-918D-4540-9991-E0D622F302A7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jacky Y Suen
@es
Jacky Y. Suen
@en
Jacky Y. Suen
@nl
Jacky Y. Suen
@sl
type
label
Jacky Y Suen
@es
Jacky Y. Suen
@en
Jacky Y. Suen
@nl
Jacky Y. Suen
@sl
prefLabel
Jacky Y Suen
@es
Jacky Y. Suen
@en
Jacky Y. Suen
@nl
Jacky Y. Suen
@sl
P1053
G-4077-2015
P106
P1153
35081233700
P21
P31
P3829
P496
0000-0002-0309-2524
P569
2000-01-01T00:00:00Z